Who is sponsoring NCT02616055?

NCT02616055 is sponsored by Kadmon Corporation, LLC.

What drugs are being tested in NCT02616055?

Interventions in NCT02616055: tesevatinib.

What condition does NCT02616055 study?

NCT02616055 studies Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Is NCT02616055 still recruiting?

NCT02616055 is currently terminated. Last updated 25 May 2022.

Last reviewed 2022-05-25 · How we verify

NCT02616055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Terminated Phase 2 Last updated 25 May 2022

What this trial tests

Phase 2 trial testing tesevatinib in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in 15 participants. Terminated before completion.

Timeline

25 December 2015

Primary endpoint
21 December 2016

21 December 2016

Quick facts

Lead sponsor	Kadmon Corporation, LLC
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	25 December 2015
Primary completion	21 December 2016
Estimated completion	21 December 2016
Sites	6 locations across United States

Drugs / interventions tested

tesevatinib — full drug profile →

Conditions studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD) — all drugs for Autosomal Dominant Polycystic Kidney Disease (ADPKD) →

Sponsor

Kadmon Corporation, LLC — full company profile →

Who can join

Adults 18 to 62, any sex, with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects who received tesevatinib in Study KD019-101 and completed 24 months of treatment will continue on the dose of tesevatinib they were receiving at 24 months on the KD019-101 study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing.
Sieben CJ, Harris PC. · · 2023 · cited 23× · PMID 37418622 · DOI 10.34067/kid.0000000000000209
Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
Wang J, Tripathy N, Chung EJ. · · 2020 · cited 14× · PMID 32866560 · DOI 10.1016/j.addr.2020.08.011
Emerging Therapies for Childhood Polycystic Kidney Disease.
Sweeney WE, Avner ED. · · 2017 · cited 4× · PMID 28473970 · DOI 10.3389/fped.2017.00077

Verify or expand the search:

Other recruiting trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Currently open trials in the same condition.

NCT07161037 — Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) · Phase 2 · recruiting
NCT06747572 — Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease · active not recruiting
NCT07355114 — Robotic vs Open Nephrectomy for ADPKD · active not recruiting
NCT07535385 — RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYC · recruiting

Other Kadmon Corporation, LLC trials

Trials by the same sponsor.

NCT04735822 — A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability · EARLY_PHASE1 · completed
NCT03907540 — Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025 · Phase 1 · completed
NCT03530995 — Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers · Phase 1 · completed
NCT03096080 — A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Pol · Phase 1 · completed
NCT02852967 — A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Se · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02616055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kadmon Corporation, LLC
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02616055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing